Frank Karbe Biography and Net Worth

Frank Karbe has over twenty-five years of financial and life-sciences expertise and currently serves as President and Chief Executive Officer of Better Therapeutics, Inc (NASDAQ: BTTX).

Prior to Better Therapeutics, he was President and Chief Financial Officer of Myovant Sciences (NYSE:MYOV). Mr. Karbe previously served as Executive Vice President and Chief Financial Officer at Exelixis, Inc., (NASDAQ: EXEL) where he drove the biopharma company’s transformation from discovery to commercialization.

Earlier in his career, Mr. Karbe worked as an investment banker for Goldman Sachs & Co. focusing on corporate finance and mergers and acquisitions in the life sciences industry. He has previously served on the Board of Directors of Aduro Biotech, Arbutus Biopharma Corporation, and Kolltan Pharmaceuticals, Inc.

Mr. Karbe holds a Diplom-Kaufmann (MBA) from the WHU Otto Beisheim School of Management in Koblenz, Germany.

What is Frank Karbe's net worth?: The estimated net worth of Frank Karbe is at least $837.90 thousand as of December 13th, 2024. Karbe owns 57,000 shares of Phathom Pharmaceuticals stock worth more than $837,900 as of December 5th. This net worth evaluation does not reflect any other investments that Karbe may own. Learn More about Frank Karbe's net worth.
How do I contact Frank Karbe?: The corporate mailing address for Karbe and other Phathom Pharmaceuticals executives is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. Phathom Pharmaceuticals can also be reached via phone at 877-742-8466 and via email at [email protected]. Learn More on Frank Karbe's contact information.
Has Frank Karbe been buying or selling shares of Phathom Pharmaceuticals?: Frank Karbe has not been actively trading shares of Phathom Pharmaceuticals during the last quarter. Most recently, on Friday, December 13th, Frank Karbe bought 12,500 shares of Phathom Pharmaceuticals stock. The stock was acquired at an average cost of $7.93 per share, with a total value of $99,125.00. Following the completion of the transaction, the director now directly owns 57,000 shares of the company's stock, valued at $452,010. Learn More on Frank Karbe's trading history.
Who are Phathom Pharmaceuticals' active insiders?: Phathom Pharmaceuticals' insider roster includes Terrie Curran (Insider), Molly Henderson (CFO), Frank Karbe (Director), Azmi Nabulsi (COO), Asit Parikh (Director), David Socks (Director), and James Topper (Director). Learn More on Phathom Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Phathom Pharmaceuticals?: During the last year, Phathom Pharmaceuticals insiders bought shares 3 times. They purchased a total of 21,280 shares worth more than $126,715.80. During the last year, insiders at the sold shares 9 times. They sold a total of 42,342 shares worth more than $284,083.77. The most recent insider tranaction occured on November, 3rd when insider Robert Charles Breedlove sold 524 shares worth more than $7,079.24. Insiders at Phathom Pharmaceuticals own 23.0% of the company. Learn More about insider trades at Phathom Pharmaceuticals.
Information on this page was last updated on 11/3/2025.

Frank Karbe Insider Trading History at Phathom Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/13/2024	Buy	12,500	$7.93	$99,125.00	57,000

Frank Karbe Buying and Selling Activity at Phathom Pharmaceuticals

Phathom Pharmaceuticals Company Overview

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Today's Range

Now: $14.70

$14.27

$14.91

50 Day Range

MA: $13.53

$10.84

$15.60

2 Week Range

Now: $14.70

$2.21

$16.26

Volume

529,916 shs

Average Volume

812,243 shs

Market Capitalization

$1.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43